Jialin Qian
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Real-world outcomes of trastuzumab deruxtecan as second- or further-line treatment in patients with HER2-mutant metastatic non-small cell lung cancer: a retrospective study.
Journal: Translational lung cancer research
Published: August 06, 2025
Cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer: a phase II clinical trial.
Journal: Nature communications
Published: July 03, 2025
Enhancing the precision of auxiliary diagnosis for lung cancer through use of SHOX2 and RASSF1A methylation status in lung biopsy and lymph node biopsy specimens.
Journal: Translational lung cancer research
Published: January 25, 2025
Efficacy and safety of first-line sintilimab plus anlotinib versus chemotherapy for metastatic non-small cell lung cancer: a phase II, open-label, randomized controlled trial.
Journal: Cancer communications (London, England)
Published: June 24, 2024
Neoadjuvant immunology therapy in patients with non-small cell lung cancer and chronic obstructive pulmonary disease.
Journal: Journal of thoracic disease
Published: May 17, 2024
Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations.
Journal: Frontiers in oncology
Published: December 19, 2023
Immunotherapy combined with chemotherapy for patients with pulmonary large cell neuroendocrine carcinoma.
Journal: Chinese medical journal
Published: October 18, 2023
Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (ALK) rearrangements and co-existing alterations-a retrospective cohort study.
Journal: Translational lung cancer research
Published: October 13, 2023
Single-cell RNA-sequencing uncovers the dynamic changes of tumour immune microenvironment in advanced lung adenocarcinoma.
Journal: BMJ open respiratory research
Published: June 08, 2023
Dynamic alterations of ctDNA associate with the therapeutic outcome in the advanced non-small cell lung cancer patients who received sintilimab plus anlotinib regime as 1st line therapy.
Journal: Clinical and translational medicine
Published: February 14, 2023
Last Updated: 09/26/2026